Search results for "ethanolamines"

showing 10 items of 65 documents

Budesonide/formoterol for maintenance and reliever therapy in the management of moderate to severe asthma.

2008

The Global Initiative for Asthma (GINA) guidelines aim at improving asthma control and preventing future risk. For patients with moderate to severe asthma an inhaled corticosteroid (ICS) or an ICS/long-acting beta2-agonist (LABA) combination with a short-acting beta2-agonist (SABA) as reliever is recommended. Despite the availability of effective maintenance therapies, a large proportion of patients still fail to achieve guideline-defined asthma control, and overuse of SABA reliever medication at the expense of ICS is commonly observed. New simplified treatment approaches may offer a solution and assist physicians to achieve overall asthma control. One such treatment approach, which is reco…

Budesonidemedicine.medical_specialtyExacerbationImmunologySeverity of Illness IndexPharmacotherapyimmune system diseasesFormoterol FumarateSeverity of illnessAdministration InhalationmedicineImmunology and AllergyAnimalsHumansAnti-Asthmatic AgentsIntensive care medicineBudesonideAsthmaInhalationbusiness.industrymedicine.diseaseAsthmarespiratory tract diseasesBudesonide/formoterolEthanolaminesPhysical therapyDrug Therapy CombinationFormoterolbusinessmedicine.drugAllergy
researchProduct

Influence of chirality on the structure of phospholipid monolayers.

1993

Molecular StructureChemistryStereochemistryPhosphatidylethanolaminesSynthetic membranePhospholipidBiophysicsMolecular ConformationStereoisomerismMembranes ArtificialStereoisomerismCrystal structureMolecular conformationBiophysical Phenomenachemistry.chemical_compoundX-Ray DiffractionMonolayerBiophysicsMoleculeChirality (chemistry)PhospholipidsResearch ArticleBiophysical journal
researchProduct

Interaction between biotin lipids and streptavidin in monolayers: formation of oriented two-dimensional protein domains induced by surface recognitio…

1989

Highly specific ligand-receptor interactions generally characterize surface recognition reactions. Such processes can be simulated by streptavidin-biotin-specific binding. Biotin lipids have thus been synthesized, and their interaction with streptavidin (or avidin) at the air-water interface was directly shown by measurement of surface pressure isotherms and fluorescence microscopy. These proteins interact with the biotin lipid monolayer via specific binding or nonspecific adsorption. Both phenomena were clearly distinguished by use of the inactivated form of streptavidin. The binding of fluorescein-labeled streptavidin to monolayers was also directly observed by fluorescence microscopy. Th…

StreptavidinChemical PhenomenaSurface PropertiesProtein domainBiotinBiochemistrychemistry.chemical_compoundBiotinBacterial ProteinsMonolayerFluorescence microscopebiologyChemistryChemistry PhysicalPhosphatidylethanolaminestechnology industry and agricultureMembranes ArtificialHydrogen-Ion ConcentrationAvidinFluorescenceLipidsSpectrometry FluorescenceSolubilityBiotinylationbiology.proteinBiophysicsSpectrophotometry UltravioletStreptavidinAvidinBiochemistry
researchProduct

Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use

2013

SummaryBackgroundIndacaterol is a once-daily, long-acting β2-agonist bronchodilator that improves dyspnoea and health status in patients with moderate-to-severe COPD. While its bronchodilator effects have been shown to be maintained in different patient subgroups, effects on clinical outcomes in certain subgroups are not yet defined.MethodsPost-hoc analysis of pooled clinical study data to investigate efficacy and safety of indacaterol compared with placebo and other long-acting bronchodilators (formoterol, salmeterol, open-label tiotropium) in patient subgroups defined by COPD severity (GOLD stage II or III; n = 4082) and ICS use at baseline (no/yes; n = 4088). Efficacy outcomes were troug…

MaleCopd patientsVital CapacityQuinolonesSeverity of Illness IndexPulmonary Disease Chronic ObstructiveForced Expiratory VolumeFormoterol FumarateBronchodilatorFormoterolSalmeterolSalmeterol XinafoateRandomized Controlled Trials as TopicIndacaterolCOPDMiddle AgedBronchodilator AgentsTreatment OutcomeEthanolaminesAnesthesiaIndansDrug Therapy CombinationFemaleSalmeterolmedicine.drugAdultPulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classScopolamine DerivativesPlaceboDrug Administration ScheduleInternal medicineAdministration InhalationmedicineHumansCOPDAlbuterolTiotropium BromideAdrenergic beta-2 Receptor AgonistsGlucocorticoidsAgedbusiness.industryTiotropiummedicine.diseaserespiratory tract diseasesDyspneaLong actingIndacaterolFormoterolbusinessRespiratory Medicine
researchProduct

Palmitoylethanolamide Promotes a Proresolving Macrophage Phenotype and Attenuates Atherosclerotic Plaque Formation

2018

Objective— Palmitoylethanolamide is an endogenous fatty acid mediator that is synthetized from membrane phospholipids by N -acyl phosphatidylethanolamine phospholipase D. Its biological actions are primarily mediated by PPAR-α (peroxisome proliferator-activated receptors α) and the orphan receptor GPR55. Palmitoylethanolamide exerts potent anti-inflammatory actions but its physiological role and promise as a therapeutic agent in chronic arterial inflammation, such as atherosclerosis remain unexplored. Approach and Results— First, the polarization of mouse primary macrophages towards a proinflammatory phenotype was found to reduce N -acyl phosphatidylethanolamine phospholipase D expression …

0301 basic medicineCannabinoid receptorTime FactorsMice Knockout ApoECHOLESTEROL TRANSPORTAnti-Inflammatory AgentsPhospholipaseProto-Oncogene Maschemistry.chemical_compoundCannabinoid receptor type 2Receptors CannabinoidAortachemistry.chemical_classificationMARROW-DERIVED CELLSAPOPTOTIC CELL ACCUMULATIONPlaque AtheroscleroticCell biologymacrophagesDENSITY-LIPOPROTEIN RECEPTORPhenotypeREDUCES INFLAMMATIONCB2 RECEPTOREthanolaminesFemaleCardiology and Cardiovascular MedicineSCAVENGER RECEPTORAortic DiseasesPalmitic Acidsta3111fatty acidsCell Line03 medical and health sciencesMediatorPhagocytosisPhospholipase DAnimalsHumansScavenger receptorCANNABINOID RECEPTORPhosphatidylethanolaminePalmitoylethanolamidec-Mer Tyrosine KinaseFatty acidcholesterolta3121AmidesRatsMice Inbred C57BLDisease Models Animal030104 developmental biologychemistryinflammationRECEPTOR CLASS-BatherosclerosisCONTACT ALLERGIC DERMATITISArteriosclerosis Thrombosis and Vascular Biology
researchProduct

Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats.

2006

Nebivolol is a β 1 -receptor antagonist with vasodilator and antioxidant properties. Because the vascular NADPH oxidase is an important superoxide source, we studied the effect of nebivolol on endothelial function and NADPH oxidase activity and expression in the well-characterized model of angiotensin II–induced hypertension. Angiotensin II infusion (1 mg/kg per day for 7 days) caused endothelial dysfunction in male Wistar rats and increased vascular superoxide as detected by lucigenin-derived chemiluminescence, as well as dihydroethidine staining. Vascular NADPH oxidase activity, as well as expression at the mRNA and protein level, were markedly upregulated, as well as NOS III uncoupled, …

Malerac1 GTP-Binding Proteinmedicine.medical_specialtyLuminescenceEndotheliumNitric Oxide Synthase Type IIIAdrenergic beta-AntagonistsNitric OxideFluorescenceCell LineNebivololchemistry.chemical_compoundHemoglobinsSuperoxidesInternal medicineInternal MedicinemedicineAnimalsHumansBenzopyransRats WistarCyclic GMPNitritesOxidase testNADPH oxidaseLuminescent AgentsbiologyChemistrySuperoxideAngiotensin IIMyocardiumNADPH OxidasesDicarbethoxydihydrocollidinePhosphoproteinsAngiotensin IINebivololRatsNitric oxide synthasemedicine.anatomical_structureEndocrinologyEthanolaminesNOX1biology.proteinAcridinesBlood VesselsLuminolEndothelium Vascularmedicine.drugSignal TransductionHypertension (Dallas, Tex. : 1979)
researchProduct

Liver fatty acid composition in the spontaneously diabetic BB rat.

1991

The purpose of the present experiment was to investigate if the modulation by insulin of liver microsomal desaturase activities in the spontaneously diabetic adult male Bio-Breeding (BB) rat, with destructive insulitis resembling the lesions described in the human Type I (insulin-dependent) diabetes, corresponds to modifications in fatty acid composition, reflect of changes in fatty acid desaturation. We observed no significant differences between BB rats, during the hyper-(48 h), the normo-(17 h) and the hypo-glycemic (3 h) periods which followed the insulin injection, and control rats for the fatty acid composition of liver total lipids, phosphatidylethanolamines, phosphatidylcholines, tr…

Fatty Acid DesaturasesMalemedicine.medical_specialtymedicine.medical_treatmentLinoleic acidArachidonic AcidsBiologyDiabetes Mellitus ExperimentalLinoleic Acidchemistry.chemical_compoundDiabetes mellitusInternal medicinemedicineAnimalsInsulinRats Inbred BBTriglycerideschemistry.chemical_classificationArachidonic AcidCholesterolInsulinPhosphatidylethanolaminesFatty AcidsFatty acidGeneral Medicinemedicine.diseaseLipid MetabolismRatsEndocrinologychemistryLinoleic AcidsLiverMicrosomeMicrosomes LiverPhosphatidylcholinesArachidonic acidCholesterol EstersInsulitisArchives internationales de physiologie, de biochimie et de biophysique
researchProduct

Inhalable Formulation Based on Lipid–Polymer Hybrid Nanoparticles for the Macrophage Targeted Delivery of Roflumilast

2022

Here, novel lipid-polymer hybrid nanoparticles (LPHNPs), targeted to lung macrophages, were realized as potential carriers for Roflumilast administration in the management of chronic obstructive pulmonary disease (COPD). To achieve this, Roflumilast-loaded fluorescent polymeric nanoparticles, based on a polyaspartamide-polycaprolactone graft copolymer, and lipid vesicles, made from 1,2-dipalmitoyl-sn-glycero-3-phosphocholine and 1,2-distearoyl-sn-glycero-phosphoethanolamine-N-(polyethylene glycol)-mannose, were properly combined using a two-step method, successfully obtaining Roflumilast-loaded hybrid fluorescent nanoparticles (Man-LPHFNPs@Roflumilast). These exhibit colloidal size and a ne…

CyclopropanesPolymers and PlasticsPolymersMacrophagesPhosphatidylethanolaminesAminopyridinesBioengineeringPolyethylene GlycolsBiomaterialsSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoBenzamidesMaterials ChemistryHumansNanoparticlesParticle SizeMannoseBiomacromolecules
researchProduct

High-performance liquid chromatographic study of the regulation of phospholipid metabolism in cultured adrenocortical cells

1994

Abstract A rapid high-performance liquid chromatographic (HPLC) method for the separation of phospholipids was developed for minute samples of total lipids (ca. 200 μg). The method was applied to the study of the phospholipid metabolism in adrenocortical cell cultures. A complete separation of the different cellular phospholipid classes was achieved in 40 min. Good resolution of the phospholipid peaks was obtained, which allowed the collection of each individual class of phospholipids for further analysis of radioactivity and fatty acid composition by gas chromatography. When cells were incubated with [U-14C]glycerol or [U-14C]palmitate the bulk of the radioactivity was found in cellular ph…

GlycerolCardiolipinsPalmitatesPhospholipidHigh-performance liquid chromatographyMicechemistry.chemical_compoundTumor Cells CulturedGlycerolmedicineAnimalsCells CulturedChromatography High Pressure LiquidPhospholipidschemistry.chemical_classificationChromatographyAdrenal cortexPhosphatidylethanolaminesGeneral ChemistryMetabolismAdrenal Cortex NeoplasmsIn vitromedicine.anatomical_structurechemistryBiochemistryCell cultureAdrenal CortexPhosphatidylcholinesTetradecanoylphorbol AcetateIndicators and Reagentslipids (amino acids peptides and proteins)Polyunsaturated fatty acidJournal of Chromatography B: Biomedical Sciences and Applications
researchProduct

Fluticasone propionate/formoterol: a fixed-combination therapy with flexible dosage.

2014

International guidelines describe asthma control as the main outcome of asthma management. Prevention of symptoms, improved quality of life, and reduction of exacerbations are the main components, consequently decreasing health care costs. However, many of these objectives remain unmet in real life: several surveys show that a large proportion of asthmatic patients are not well controlled despite the efficacy of current available treatment. Several randomized controlled clinical trials indicate that combining inhaled corticosteroids and long-acting β2-agonists, by means of a single inhaler, greatly improves the management of the disease. The results of 9 multicenter phase III clinical studi…

medicine.medical_specialtyCombination therapyAsthma exacerbationSettore MED/10 - Malattie dell'Apparato RespiratorioSettore MED/10 - Malattie Dell'Apparato RespiratorioFluticasone propionateAsthma control; Asthma exacerbations; Fixed-combination therapy; Fluticasone propionate/formoterol; Single-aerosol inhalerAsthma controlFluticasone propionate/formoterolForced Expiratory VolumeFormoterol FumarateInternal MedicineMedicineHumansAnti-Asthmatic AgentsAsthma exacerbationsParticle SizeIntensive care medicineAsthmaFluticasonebusiness.industryInhalerNebulizers and VaporizersFixed-combination therapyAsthma control; Asthma exacerbations; Fixed-combination therapy; Fluticasone propionate/formoterol; Single-aerosol inhaler; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Drug Combinations; Ethanolamines; Fluticasone; Forced Expiratory Volume; Formoterol Fumarate; Humans; Nebulizers and Vaporizers; Particle Size; Quality of Life; Treatment Outcomemedicine.diseaseSingle-aerosol inhalerAsthmaBronchodilator AgentsAndrostadienesDrug CombinationsTreatment OutcomeTolerabilityAsthma control Asthma exacerbations Fixed-combination therapy Fluticasone propionate/formoterol Single-aerosol inhalerEthanolaminesAnesthesiaAsthma exacerbations; Asthma control; Fixed-combination therapy; Fluticasone propionate/formoterol; Single-aerosol inhalerQuality of LifeFluticasoneFormoterol FumarateFormoterolbusinessmedicine.drugEuropean journal of internal medicine
researchProduct